Subscribe free

Intestine and Lower Gastrointestinal Tract ·

Conversion Surgery Reduces Mortality in Metastatic Colorectal Cancer

Conversion surgery significantly reduced mortality risk by 42% in patients with unresectable metastatic colorectal cancer treated with anti-EGFR agents and bevacizumab. Subgroup analyses showed reduced risks of mortality in patients with specific characteristics. While targeted therapy reduced mortality risk, the difference was not statistically significant between the two treatment groups. Conversion surgery may explain the disparity in survival outcomes between anti-EGFR agents and bevacizumab in colorectal cancer patients.

Journal Article by Su CC, Su YC, Wu CC and Lee PT in Clin Colorectal Cancer

Copyright © 2024 Elsevier Inc. All rights reserved.

read the whole article in Clin Colorectal Cancer

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →